Additionally, aptamers are capable of overcoming some major problems with most of the current TNF blockers, such as immune reactions, immunosuppressions, increased risk of serious infections and high costs (Menegatti et al., 2019; Croft and Siegel, 2017). Here, TNF is linked to infection.